MOTS‐c promotes phosphorodiamidate morpholino oligomer uptake and efficacy in dystrophic mice
Authors:
Open Access
- 18 December 2020
- journal article
- research article
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 13 (2) , e12993
Abstract
Antisense oligonucleotide (AO)‐mediated exon‐skipping therapies show promise in Duchenne muscular dystrophy (DMD), a devastating muscular disease caused by frame‐disrupting mutations in the DMD gene. However, insufficient systemic delivery remains a hurdle to clinical deployment. Here, we demonstrate that MOTS‐c, a mitochondria‐derived bioactive peptide, with an intrinsic muscle‐targeting property, augmented glycolytic flux and energy production capacity of dystrophic muscles in vitro and in vivo , resulting in enhanced phosphorodiamidate morpholino oligomer (PMO) uptake and activity in mdx mice. Long‐term repeated administration of MOTS‐c (500 μg) and PMO at the dose of 12.5 mg/kg/week for 3 weeks followed by 12.5 mg/kg/month for 3 months (PMO‐M) induced therapeutic levels of dystrophin expression in peripheral muscles, with up to 25‐fold increase in diaphragm of mdx mice over PMO alone. PMO‐M improved muscle function and pathologies in mdx mice without detectable toxicity. Our results demonstrate that MOTS‐c enables enhanced PMO uptake and activity in dystrophic muscles by providing energy and may have therapeutic implications for exon‐skipping therapeutics in DMD and other energy‐deficient disorders.Keywords
Funding Information
- National Key R&D Programme of China (2017YFC1001902)
- National Natural Science Foundation of China (81672124)
- National Natural Science Foundation of China (82030054)
- National Natural Science Foundation of China (81802124)
This publication has 43 references indexed in Scilit:
- Frequently abnormal serum gamma-glutamyl transferase activity is associated with future development of fatty liver: a retrospective cohort studyBMC Gastroenterology, 2020
- Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophyNeurology, 2020
- Impaired Glucose Tolerance in Adults with Duchenne and Becker Muscular DystrophyNutrients, 2018
- Long-Term Morpholino Oligomers in Hexose Elicit Long-Lasting Therapeutic Improvements in mdx MiceMolecular Therapy Nucleic Acids, 2018
- Anchor peptide captures, targets, and loads exosomes of diverse origins for diagnostics and therapyScience Translational Medicine, 2018
- Delivery is key: lessons learnt from developing splice‐switching antisense therapiesEMBO Molecular Medicine, 2017
- Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx miceNature Communications, 2016
- Effective Dystrophin Restoration by a Novel Muscle-Homing Peptide–Morpholino Conjugate in Dystrophin-Deficient mdx MiceMolecular Therapy, 2014
- The Influence of Antisense Oligonucleotide Length on Dystrophin Exon SkippingMolecular Therapy, 2007
- Blood Monocytes Consist of Two Principal Subsets with Distinct Migratory PropertiesImmunity, 2003